News IRLAB Therapeutics AB

Stocks

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm 20:00:00 04/09/2026 +04			5-day change	1st Jan Change
1.710 ^SEK	-0.70%		-4.36%	-13.20%

09-03	Irlab CEO Kristina Torfgaard to step down in 2027	FW
09-03	Irlab CEO Kristina Torfgaard wants to step down	FW

All News

Mentions Relevance

09-03	IRLAB's CEO Intends to Step Down During the First Quarter of 2027	AQ
09-03	Irlab CEO Kristina Torfgaard to step down in 2027	FW
09-03	Irlab CEO Kristina Torfgaard wants to step down	FW
09-03	Irlabs CEO to step down in Q1 2027	FW
09-03	IRLAB’s CEO intends to step down during the first quarter of 2027	AQ
08-31	New number of shares and votes in IRLAB Therapeutics AB	AQ
08-28	Redeye sets a justified value of 6.60 kronor for Irlab, partnerships remain in focus	FW
08-26	IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-26	Irlab cuts revenue and operating loss	FW
08-26	IRLAB publishes interim report for the period January - June 2026	AQ
08-20	IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast	AQ
08-19	IRLAB's Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO	AQ
08-19	Irlab's IRL757 is assigned the name linepemat by WHO	FW
08-19	IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO	AQ
08-19	IRLAB Therapeutics AB's Drug Candidate IRL757 Receives Generic Name Linepemat From WHO And Provides Update On Clinical Development	CI
07-31	New number of shares and votes in IRLAB Therapeutics AB	AQ
07-10	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
07-08	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
06-30	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI
06-30	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
06-30	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln	RE
06-30	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering	MT
06-30	Irlab rights issue oversubscribed	FW
06-16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
06-16	Irlab highlights positive data for mesdopetam	FW